Conventional and new antidepressant drugs in the elderly
Introduction
Depression in the elderly is nowadays a predominant health care problem, mainly due to the progressive aging of the population. In fact, the statistics of the United Nations and the World Bank pointed out that by the year 2010 approximately 7.3% of the world’s population will be over the age of 65 and by the year 2030 a further increase up to 20% is foreseen (Mendlewicz, 1998). Depression is the most common psychiatric disease in the elderly; major depression may affect from 10 to 20% of hospitalized elderly, while from 10 to 34.5% of older persons in the community may have depressive symptoms if mild forms are considered too (Blazer, 1989, Murphy et al., 1988, Small, 1991, Weissman et al., 1988, Linden et al., 1998). In the Consensus Statement on the Diagnosis and Treatment of Depression in Late Life (National Institute of Health), it was emphasized that depression in the elderly is a persistent or recurrent disorder resulting from psychosocial stress or physiologic effects of disease and can lead to disability, cognitive impairments, increased symptoms from medical illness, increased utilization of health care services and increased rates of suicide and nonsuicide mortality (Katz et al., 1994).
Data from Diagnostic and Statistical Manual for Mental Disorders, 4th edition (DSM-IV) have shown that major depressive disorder is more frequent in young people, whilst dysthymia and depressive disorder not otherwise specified prevail among the elderly (Gottfries, 1998). These results don’t mean that depression is less severe in elderly people than in younger, since high suicide rates have been especially found in the former.
Moreover, depression is difficult to diagnose in elderly people; depressive symptoms are often masked by somatic complaints or by cognitive symptoms, conditions once called ‘masqued depression’ or ‘pseudodemence’. Therefore, depression in the elderly is often under-recognized and under-treated (Lecrubier, 1998); this may be due to the mistake, both from the physician and from the patient, of considering depression as a physiologic response to aging. Other factors may be the lack of consciousness of disease from the patient, the presence of concomitant diseases, especially dementia (Bayer and Pathy, 1989) and the usully atypical onset of depression in elderly people (Blazer, 1980). The increased incidence and prevalence of depression with aging can be also explained considering some stressors which elderly people frequently have to face, such as physical disability, bereavement, loss of prestiges, cognitive abilities and social isolation (Koenig and Blazer, 1992). In fact, it was shown that the nature and quality of social support, defined by the number of relationships with friends and relatives is one of the major risk factors for depression in the elderly (Krause et al., 1989, Russel and Cutrona, 1991, Owmank et al., 1992). Female sex, widowhood and single life are risk factors for depression too (Dufouil et al., 1995, Blazer et al., 1991, Okwumabua et al., 1997). Interestingly, some studies have shown that aging itself is not a risk factor for depression (Blazer et al., 1991, Roberts et al., 1997).
Moreover, major depression may arise from disfunction of the limbic-hypothalamic-pituitary-adrenal axis (Friedlander et al., 1993). Depression may also be caused by a various number of drugs currently administered (see below); this is remarkable especially in elderly people, where polypathology is often associated to polypharmacotherapy. Depression has also global consequences on quality of life and social functioning, leading to distress, loss of role and gratification, narrowing of the social repertoire and shortening of life span (Warner, 1998). In fact, mortality may also be higher in the elderly depressed compared with controls (Murphy, 1983); the excess mortality was accounted for by a variety of diseases, such as vascular and respiratory diseases and cancer.
Section snippets
Incidence and prevalence of depression in the elderly
Epidemiologic studies of depression in the elderly raise a number of methodological problems, because of various reasons, such as the lack of a clear definition of elderly, the different populations studied (i.e. general population, patients in primary care units, instituzionalized patients, etc.), the methods of assessment used (self-rating scales, short or structured interviews, diagnostic criteria check lists) (Lepine and Bouchez, 1998). Among the methods of assessment the Zung Self Rating
Symptomatology and aetiology of depression in the elderly
Depressive disorder in younger people is often described as a tetrahedron of symptoms, where depressed mood, anxiety, reduced activity and somatic symptoms are the four corners. In elderly people, we need to distinguish depressive illness from psychological disturbances secondary to other diseases (Table 2). Depression and such secondary disturbances often occur in the same patient in the elderly.
In contrast to younger depressed patients, elderly patients often avoid reporting or showing that
Age-related changes in pharmacokinetics
Age-related changes in pharmacokinetics and pharmacodynamics may cause an increase in adverse drug reactions (ADRs) in the elderly persons. In fact, aging causes a number of changes in drug absorption, distribution, biotransformation and elimination (Galeotta et al., 1990; Voltz and Moeller, 1994). Drug pharmacokinetics may change with age as a consequence of living habits in elderly subjects, such as diet, alcohol consumption, smoking, concomitant use of other drugs and genetic polymorphism of
Mechanism of action of antidepressants
The underlying biochemical events in endogenous depression are still unknown. A disregulation of the Central Nervous System (CNS) involving the neurotransmitters NA, 5-HT and DA has been suggested and the mainstream of research in depression has principally focused on NA and 5-HT systems as having many drug development programmes. Currently, the most efficacious treatment of major and related depression, obsessive compulsive disorders and panic attacks is considered to be an increase in 5-HT
Antidepressant drugs in the elderly
The conventional drugs used in depression are:
- 1.
tricyclic antidepressants (TCAs);
- 2.
selective serotonin reuptake inhibitors (SSRI) and other new atypical antidepressants;
- 3.
MAO inhibitors (IMAOs);
- 4.
Mood stabilizing drugs, such as lithium, carbamazepine, phenytoin, valproate, verapamil, lamotrigine and gabapentin.
In this review we are going to see those drugs having clinical
Electroconvulsive therapy
Electroconvulsive therapy may be used in those patients in whom pharmacological therapy was not effective and/or have an high risk of suicide. The most common side effect is a transient loss of memory, which might be avoided through the stimulation of nondominant hemisphere. Moreover the increased intracranial pressure might induce the herniation of brain tissue through tentorium. All the subjects with osteoporosis may undergo fractures for convulsive movements. Further research involving
Conclusions
Depression is a common but treatable condition in the elderly, which is often hard to diagnose, as it may be masked by hypochondriasis or somatization. Special problems in diagnosis also derives from bipolar disorder, pseudodementia, pathological grief and organic mood disorder as those related to medications or physical illness (Casey, 1994). The difficulties in diagnosing depression may lead to unnecessary investigations, delay in treatment and an increased risk of suicide, especially in men.
Acknowledgements
This research was supported by Ministero dell’Universita e della Ricerca Scientifica e Tecnologica (MURST).
References (349)
- et al.
Localization of the 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera
Neuropharmacol
(1995) - et al.
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
Lancet
(1993) - et al.
Blockade by newly develop antidepressants of biogenic amine uptake into rat brain synaptosomes
Life Sci
(1993) - et al.
Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA
Brain Res
(1991) - et al.
Dopaminergic receptor in the anterior pituitary gland
J. Biol. Chem
(1978) - et al.
Structure and function of adrenergic receptor: models for understanding G protein coupled receptor
- et al.
A 5-hydroxytryptamine-2 agonist augments g-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons
Neurosci
(1993) - et al.
D4 dopamine receptor mediated signaling events determined in transfected Chinese hamster ovary cells
J. Biol. Chem
(1994) - et al.
[]-spiperone labels dopamine receptors in pituitary and brain
Eur. J. Pharmacol
(1977) - et al.
Are increases in GABAB receptors consistent findings following chronic antidepressant administration?
Eur. J. Pharmacol
(1987)
Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain
Neuroscience
Imipramine and desipramine disposition in the elderly
J. Pharmac. Exp. Ther
The prognosis of depression in old age: the case for lithium therapy
Br. J. Psychiatry
Steady state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy
B. M. J
Sedativo-ipnotici ed ansiolitici anche nell’anziano
Geriatrics
Clinical pharmacokinetics of fluoxetine
Clin. Pharmacokinet
Non-insulin-dependent diabetes mellitus is associated with a greater prevalence of depression in the elderly. The Osservatorio Geriatrico of Campania Region Group
Diabetes Metab
The pharmacology of reversible monoamine oxidase inhibitors
Br. J. Psychiatry
Biochemical and pharmacological characterization of []GBR 12935 binding in vitro to rat striatal membranes: labelling of the dopamine uptake complex
J. Neurochem
Characterization of the discriminative stimulus properties induced by 5-HT1 and 5-HT2 agonists in rats
Pharmac. and Toxicol
Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an ionophoretic study
Synapse
Sertraline: a new antidepressant
Am. Fam. Physician
Therapeutic drug monitoring. Relevance during the drug treatment of psychiatric disorders
CNS Drugs
Depression in late life. A comparison of symptoms and risk factors in early and late onset cases
Br. J. Psychiatry
Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan
Br. J. Clin. Pharmacol
Valproic acid clearance: unbound fraction and diurnal variations in young and elderly adults
Clin. Pharmacol. Ther
Pharmacokinetic and pharmacodynamic relationship of the selective serotonin reuptake inhibitors
Clin. Pharmacokinet
Care of depression in the elderly: comparative pharmacokinetics of SSRIs
Int. Clin. Psychopharmac
Identification of depression in geriatric medical patients
Fluoxetine versus trazodone: efficacy and activating-sedating effects
J. Clin. Psychiatry
Risk factors in geriatric drug prescribing
Drugs
Depression in the elderly living in the community. Its presentation and features
Br. J. Psychiatry
Neuropharmacology of St. John’s wort (Hypericum)
Ann. Pharmacother
Depressive symptoms in relation to physical health and functioning in the elderly
Am. J. Epidemiol
5-HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orfenadrine and placebo
Clin. Neuropharmacol
Amineptin dependence. Detection of patients at risk. Report of 8 cases
Encephale
The diagnosis of depression in the elderly
JAGS
Depression in the elderly
N. Engl. J. Med
The association of age and depression among the elderly: an epidemiologic exploration
J. Gerontol
Epidemiology of disphoria and depression in an elderly population
Am. J. Psychiatry
A role for the serotonin system in the mechanism of action of antidepressants
J. Clin. Psychiatry
Development and validation of a social functioning scale, the social adaptation self-evaluating scale
Eur. Neuropsychopharmacol
Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry
Ther. Drug Monitor
Fluoxetine in elderly patients: is there cause for concern?
JAGS
Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease
J. Clin. Psychiatry
Cloning expression of a rat D2 dopamine receptor cDNA
Nature
Subtypes of α1- and α2-adrenergic receptors
FASEB
Effect of posture on blood pressure in the elderly
Br. Heart J.
Cited by (125)
Monoamine oxidases in age-associated diseases: New perspectives for old enzymes
2021, Ageing Research ReviewsCitation Excerpt :While the first generation of inhibitors (characterized by a nonselective and irreversible binding on both MAO isoforms) provoked severe hypertensive crises, more recent research resulted in the development of selective and reversible inhibitors for each isoform. Henceforth, the reversible MAO-A inhibitors, especially moclobemide, have been reported to be particularly effective in the treatment of depression in elderly patients (Gareri et al., 2000), where other antidepressants have no beneficial effects (Tham et al., 2016). This suggests that MAO-A inhibitors could be of great therapeutic interest in the treatment of age-related depression.
A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review
2020, European Journal of Medicinal ChemistrySynthesis and structural elucidation of novel antifungal N-(fluorophenyl)piperazinyl benzoxaboroles and their analogues
2019, Journal of Molecular StructurePrivileged scaffolds as MAO inhibitors: Retrospect and prospects
2018, European Journal of Medicinal ChemistryMajor depression and heart failure: Interest of monoamine oxidase inhibitors
2017, International Journal of CardiologyCitation Excerpt :Their indication is currently limited to treatment-resistant major depression. However, irreversible and non-selective MAOIs are free from anticholinergic or antihistaminic effects [42,54]. Despite their effects on blood pressure, they are relatively free from direct cardiac side effects when dietary restrictions are followed [54,55].
Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one
2017, European Journal of Medicinal Chemistry